Background-This study compared generalized complex fractionated atrial electrograms (CFAE) ablation versus a selective CFAE ablation strategy targeting areas of continuous electric activity. Methods and Results-Subjects with symptomatic, persistent/high-burden paroxysmal atrial fibrillation (AF) were enrolled at 6 centers (n=86) and randomized to 1 of 2 arms. For group I, all CFAE regions with an interval confidence level >7 were ablated followed by pulmonary vein isolation (PVI). For group II, only CFAE sites with continuous electric activity were ablated followed by PVI. For PVI, all 4 PV antra were isolated with confirmed entrance block. Subjects were followed for 1 year with a visit, ECG, and 48-hour Holter every 3 months. Symptoms were confirmed by loop recording. The primary end point was freedom from arrhythmia >30 seconds at 1 year. For both group I and II, CFAE ablation prolonged AF cycle length (25±33 versus 23±33 ms; P=0.78) and resulted in similar rates of AF termination (37% versus 28%; P=0.42). Radiofrequency duration during CFAE ablation was significantly less in group II (23±20 versus 38±20 minutes; P=0.002). At 1-year follow-up, freedom from AF/atrial flutter/atrial tachycardia recurrence was significantly higher in group I versus group II after 1 procedure (50% versus 28%; P=0.03). There were also significantly fewer repeat procedures in group I (13% versus 36%; P=0.021). Conclusions-Continuous electric activity ablation+PVI result in a similar incidence of acute AF termination with significantly less radiofrequency time. However, incidence of repeat procedures and long-term recurrence of AF/atrial flutter/atrial tachycardia are significantly lower using generalized CFAE ablation+PVI. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00926783 (Circ Arrhythm Electrophysiol. 2014;7:55-62.)
M ethods of atrial fibrillation (AF) ablation have focused on elimination of the triggers of AF or on modification of the substrate responsible for AF perpetuation. In particular, complex fractionated atrial electrograms (CFAE) demonstrating either continuous fractionation or short cycle length (CL) during AF may represent critical areas responsible for the maintenance of AF. 1, 2 These regions may also represent regions of hyperactive autonomic activity within the left atrium (LA). 3 Previous data have shown that when used in combination with pulmonary vein isolation (PVI), CFAE ablation results in acute AF slowing and termination and long-term freedom from AF recurrence. 4, 5 
Clinical Perspective on p 62
Although CFAE are purported to represent critical sites crucial to AF perpetuation, some CFAE may represent sites of passive wavefront collision, which are not important to the maintenance of AF. In some subjects, CFAE regions may be expansive, covering a large surface area of both left and right atria. 6 To minimize atrial destruction and to better discriminate important CFAE sites from passive sites, more discriminating electrogram (EGM) characteristics may need to be considered. Some studies have suggested that EGMs exhibiting continuous electric activity (CEA) are most predictive of AF termination and prolongation in AFCL. 7 Whether selective ablation of CEA sites compared with generalized ablation of all CFAE sites would provide comparable efficacy with less ablation has never been tested.
Thus, the selective CFAE targeting for AF (SELECT AF) study was designed to determine whether a strategy of selective CFAE ablation specifically targeting CEA sites versus a strategy of generalized CFAE ablation, followed by PVI in both groups, would result in similar efficacy with less overall ablation.
Study Design
The SELECT AF trial was a prospective, multicenter, randomized trial. Subjects were randomized 1:1 to 1 of 2 AF adjuvant CFAE ablation strategies in addition to PVI: group I involved targeting all CFAE sites versus group II that involved targeting specific sites exhibiting CEA. Enrollment occurred at 6 centers (Southlake Regional Health Center, n=32; Royal Adelaide Hospital, n=26; Institut de Cardiologie et Pneumologie de l'Université Laval, n=11; Montreal Heart Institute, n=4; Hamilton Health Sciences Center, n=3; and Loyola University Medical Center, n=10). Data were independently collected, managed, and analyzed with a restricted access database. Written informed consent was obtained from each participant, and the study protocol received approval by the institutional ethics review board at each institution.
Patient Population
Subjects undergoing first-time ablation for symptomatic AF refractory to ≥1 antiarrhythmic drug (AAD) were enrolled. All subjects had either persistent or high-burden paroxysmal AF. Persistent AF was defined as episodes sustained for >7 days, requiring termination by cardioversion. High-burden paroxysmal AF was defined as episodes terminating within 30 days and meeting any one of the following criteria: (1) >1 episode of AF per month in the preceding 6 months with ≥1 episode lasting >24 hours by symptoms; (2) LA size of ≥48 mm in the parasternal long-axis view on echocardiography; (3) LA volume ≥100 mL; or (4) total AF history of ≥10 years. By this definition, it was hoped that the high-burden paroxysmal subjects would closely resemble persistent AF subjects. 5, 9 The study initially sought to include only persistent AF, but because the indication for the irrigated ablation catheter was restricted to paroxysmal AF only in the United States, high-burden paroxysmals had to be included. Detailed inclusion and exclusion criteria have been published previously. 8
Catheter Ablation Strategies
All subjects underwent catheter ablation using radiofrequency (RF) energy, with appropriate preablation anticoagulation and transesophageal echocardiography to rule out LA thrombus. AAD were stopped ≥5 half-lives before the procedure, except amiodarone, which was stopped before ≥8 weeks.
For ablation, a multipolar catheter (minimum 8 bipoles) was placed in the coronary sinus (CS). A decapolar, circular mapping catheter (Lasso Catheter, Biosense Webster) and a 3.5-mm open irrigated-tip ablation catheter (NaviStar ThermoCool, Biosense Webster) were introduced into the LA for mapping and ablation. All procedures were guided by an electroanatomic mapping system (Carto XP, Biosense Webster). After creation of an anatomic map of the LA, mapping of CFAE (either selective or generalized) using an automated algorithm was performed during AF. If the subject was not already in AF, it was induced by rapid atrial pacing and sustained with isoproterenol if required. Electric mapping was performed only when AF persisted for a minimum of 5 minutes. If AF could not be induced, the patient was excluded from the study. A minimum of 100 sites were sampled in a broad distribution across the LA and CS.
Group I CFAE Ablation (the Generalized Approach)
At each mapping site, a 2.5-second window of bipolar EGMs was analyzed by an online CFAE software module. In brief, voltage peaks greater than the noise threshold but less than an upper threshold (0.05-0.15 mV) were annotated. The intervals between successive peaks falling within a programmable duration (60-120 ms) were then counted, and the total was designated the interval confidence level.
All sites with interval confidence level >7 were targeted for group I CFAE ablation ( Figure 1A ). 10
Group II CFAE Ablation (the Selective or CEA Approach)
For group II CFAE ablation, only points exhibiting CEA were targeted. CEA were identified with automated, online software called the CFr or continuous fractionation module. This software quantifies the duration of each signal out of 2.5 seconds for which there are no isoelectric segments (ie, continuous deflection of the baseline). The ratio of this duration divided by the 2.5 seconds provides a percentage of CEA for each signal. Sites exhibiting >75% continuous activity were defined as CEA targeted for group II ablation ( Figure 1B ).
CFAE Ablation
CFAE ablation was performed before PVI to assess changes in AFCL and AF termination by CFAE ablation alone. RF energy was delivered at each CFAE location for ≥30 seconds at a time (max power 25 W in the CS, 35 W along the posterior LA, and 45 W at other sites, max temperature 45°C, flow rate 30 mL/min). The end point for each lesion was total elimination of the local CFAE EGM. AFCL was measured from a predetermined pair of CS recording electrodes. AF termination was defined as direct transition to sinus rhythm or to an organized atrial tachycardia (AT) or flutter (AFL). In subjects with paroxysmal AF, a minimum of 5 attempts were made to reinduce AF if AF terminated during ablation. No attempt was made to reinduce AF in subjects with persistent AF.
Wide Antral PVI
After CFAE ablation was completed, all subjects underwent PVI. In brief, circumferential ablation lesions were placed >2 cm from the PV ostia to encircle and electrically isolate the PVs. The circular catheter was used to confirm entrance block into each vein. If the subject was still in AF at the end of the procedure, the subject was cardioverted back to sinus rhythm with repeated mapping of the PVs to confirm isolation.
Repeat Ablation Procedures
Repeat ablations were allowed, and it was recommended that these occur between 3 and 6 months after the initial study procedure, using the same ablation strategy used in the first procedure.
Postablation Follow-up
AAD (except amiodarone) were allowed for the first 3 months after ablation to avoid early recurrences postablation. However, AAD were stopped after 3 months to assess for success.
Scheduled clinic follow-up visits with the physician occurred at 3, 6, 9, and 12 months. At each follow-up visit, a 12-lead ECG and 48-hour Holter were performed. Additional ECGs, Holters, and external loop recorders were also performed as indicated by subject symptoms or physician discretion.
Episodes of AF/AFL/AT >30 seconds in duration were considered a clinical recurrence (either symptomatic or asymptomatic). A blanking period of 3 months was used to censor early recurrences postablation. At the time of protocol design, these follow-up procedures were in compliance with the current Heart Rhythm Society/American Heart Association/American College of Cardiology guidelines about the design of clinical trials for AF ablation. 11
Study End Points
The primary efficacy end point of the study was freedom from atrial arrhythmia at 1 year on or off AAD after 1 procedure. The primary safety end point was total RF delivery time per procedure. Secondary end points included change in AFCL per strategy, incidence of AF termination, incidence of procedure-related adverse events, procedural duration, fluoroscopic duration, number of repeat procedures, and success after ≥1 procedures. . Voltage peaks (white dots) greater than this threshold but less than an upper threshold (±0.15 mV, blue lines) are then identified. The intervals between successive peaks falling within the voltage window and within a programmable duration (60-120 ms) are then identified (yellow dots) and counted, the sum designated the interval confidence level (ICL). In this example, the ICL is 12. In the left atrial maps at the top of A, red areas represent regions with ICL >7. B, Group II CFAE electrogram with continuous electric activity (CEA) is shown at the bottom. A programmable lower threshold for EGM identification is set to exclude noise (±0.05 mV, brown line). Voltage peaks (white dots) greater than this threshold but less than an upper threshold (±0.5 mV, blue lines) are then identified. The software then identifies isoelectric segments of >50 ms between peaks (blue segments). The remaining segments (shown in red) represent CEA. The total CEA duration divided by the sample duration represents the percent CEA for the site. This example demonstrates 88% CEA. In the left atrial maps at the top of B, red areas represent regions of CEA >75%. February 2014
Sample Size and Statistical Analysis
The study was designed as a pilot study. There are no comparative data between ablation of CEA compared with more generalized CFAE ablation on which to base the sample size calculations. We, therefore, chose a sample size of 80 patients (40 per arm) to be consistent with the sample sizes of other published comparative AF ablation pilot studies. 12, 13 Only subjects undergoing ablation with both CFAE and PVI procedures completed were included for analysis. Group characteristics were compared using the Student t test or Fisher exact test as indicated. Time to atrial arrhythmia recurrence at 12 months was compared using Kaplan-Meier analysis and the log-rank test. A P<0.05 was considered significant for all statistical determinations. Statistical analysis was performed using SAS software (version 9.2, Cary, NC).
Results

Patient Characteristics
A total of 86 subjects were enrolled in the study (Figure 2 ). Subjects were randomized into group I (n=42) or group II (n=42) CFAE ablation, respectively. Two subjects who signed consent were withdrawn before randomization because they did not meet inclusion/exclusion criteria. Four subjects in group I and 3 subjects in group II either did not end up undergoing ablation or the CFAE procedure could not be completed because of AF noninducibility, so only 77 subjects were available for analysis (n=38 group I and n=39 group II).
The characteristics of each group are detailed in Table 1 , and there were no significant differences between groups. AF was persistent in 48 subjects (62%) and high-burden paroxysmal in 29 subjects (38%).
Mapping and Ablation Details
A total of 48 subjects presented to the ablation procedure in spontaneous AF. AF had to be induced with pacing alone in 21 subjects and with pacing plus isoproterenol in 8 subjects. Baseline AFCL was 181±30 ms. A mean of 127±39 points was taken per preablation CFAE map, with a mapping time of 32±21 minutes. CFAE regions occupied 22±9% of the LA surface area in group I and 3±2% in group II (P=0.008). Further rhythm and mapping details are listed in Table 2 .
In group II, CEA regions were most commonly located in the LA septum (n=14), left atrial appendage base (n=13), LA posterior wall (n=12), and PV antral region (n=9) followed by the CS (n=9), LA floor (n=8), and LA roof (n=7). In group I, high interval confidence level regions were most commonly located in the LA posterior wall (n=29), PV antral region (n=26), LA roof (n=16), septum (n=16), LA appendage base (n=13), and LA floor (n=12). A representative CFAE map with lesion sets is shown in Figure 3 . Distribution of CFAE was similar among the patients who required AF induction with pacing or isoproterenol in both arms.
Group II and group I CFAE ablation prolonged AFCL by similar amounts (23±33 versus 25±33 ms; P=0.78) before PVI. AF termination rates were also similar between the 2 groups (28% versus 37%; P=0.42). With addition of PVI after CFAE ablation, AFCL increased to 213±48 ms in group II and 226±99 ms in group I (P=0.48). PVI also resulted in an additional 11 AF terminations in group II versus 7 in group I (P=0.21). Details of AF termination for both groups are provided in Table  2 . Termination rates and AFCL changes were not significantly different among the subset of patients who required AF induction with pacing or isoproterenol in both arms. Study flow chart for subjects in the selective complex fractionated atrial electrograms targeting for atrial fibrillation (SELECT AF) trial. A total of 86 subjects were enrolled. However, 2 did not meet inclusion/exclusion criteria, 6 were unable to undergo CFAE ablation because of AF noninducibility, and 1 had left atrial thrombus excluding ablation, leaving a total of 77 evaluable subjects. Subjects were randomized into each of the 2 study arms. All subjects completed the required follow-ups.
Total RF duration during CFAE ablation was significantly shorter in group II (23±20 minutes) versus group I (38±20 minutes; P=0.002). However, total RF duration for the combined CFAE and PVI procedure was similar for both arms (P=0.26; Table 2 ). Total procedure (P=0.67) and fluoroscopy times (P=0.56) were not significantly different between the 2 groups ( Table 2 ).
Postablation Outcomes
Mean follow-up was 382±42 days. At final follow-up, 76% of patients in group I were off AAD compared with 54% in group II (P=0.04; Table 3 ). All but one of these patients remained on AAD because of failed ablation procedures.
After 1 procedure, group I had the highest freedom from AF/AFL/AT, with a success rate of 50% compared with 28% in group II (log-rank P=0.03; Figure 4 ). Of the patients considered successful after 1 procedure, only 1 remained on an AAD (flecainide) in group II, whereas none were on AAD in group I ( Table 3 ). Most of the recurrences were documented to be AF (49%), with 31% documented as AFL and 20% documented as AT.
A total of 1.2±0.4 procedures were done per subject. Repeat procedures were performed 7±3 months after the first procedure. There were significantly more repeat procedures performed in group II compared with group I (36% versus 13%; P=0.021). After ≥1 ablation procedures, freedom from AF/AFL/ AT remained higher in group I (53%) compared with group II (33%), but this was statistically nonsignificant (P=0.087).
During the repeat procedures (n=19), AF was induced in 10 of 19 (53%) but could not be induced in the others (n=9). In the patients with inducible AF, CFAE ablation was performed according to the randomized strategy for all. CFAE were located in the LA appendage base (n=6), LA posterior wall (n=4), LA floor (n=4), septum (n=3), LA roof (n=3), and PV antral region (n=2). AF terminated in 4 of 10 patients (2 to sinus and 2 to AFL); the patients who did not terminate to sinus were cardioverted. PV reconnection was found in 18 of 
patients (95%) undergoing repeat ablation. Repeat isolation was performed on a mean of 3±1 PVs per patient.
When the persistent and high-burden paroxysmal subgroups were analyzed separately, the persistent group I arm still had a significantly higher freedom from AF/AFL/AT compared with the persistent group II arm (54% versus 22%, respectively; P=0.02). In the high-burden paroxysmal group, there was no significant difference between the success rates of the 2 groups, although the total number of subjects was small (44% group I versus 42% group II; P=0.68).
In the subset of patients who required pacing or isoproterenol to induce AF, the success rate for each arm was similar to the overall group of patients (50% for group I and 25% for group II; P=0.04).
Adverse Events
Procedure-related adverse events are detailed in Table 4 . Serious adverse events included 1 subject in group I who developed cardiac tamponade during ablation, which was successfully treated with percutaneous drainage. Two subjects in group II and 1 in group I developed hypotension or apnea secondary to oversedation, which was quickly reversed. One patient in group I developed partial right phrenic nerve palsy (asymptomatic, diagnosed on chest radiography), which subsided within 6 months. There were no cases of stroke, transient ischemic attack, symptomatic pulmonary vein stenosis, atrial esophageal fistula, or death.
Discussion
Main Findings
This randomized, multicenter study demonstrates that a strategy of selective CFAE ablation, targeting only regions of CEA (group II), is not as effective as a more generalized CFAE ablation strategy (group I) in combination with PVI. Group II CFAE ablation required less RF time compared with group I and resulted in similar rates of AF slowing and termination. However, when combined with PVI, the RF times for both strategies were similar. Furthermore, success rate at 1 year after 1 procedure was significantly better in group I. Group I also resulted in a significantly lower number of repeat procedures. This is the first randomized trial to compare the effects of different strategies of CFAE ablation on outcome when combined with PVI.
Selective Versus Generalized CFAE Regions
The original clinical definition of CFAE includes >1 type of EGM: those with CEA and those with short CLs (<120 ms). 4 Thus, CFAE may encompass a somewhat heterogeneous set of EGMs. CFAE may also represent multiple different mechanisms for AF perpetuation including critical pivot points within the atria, 1 sites of autonomic ganglionic input, 3 or fibrillatory rotors. 14 Other CFAE sites may be caused by passive wavefront collision, which are not important to the fibrillatory process. Whether different subsets of CFAE represent different mechanisms for AF perpetuation is, unfortunately, not well known. Yet, when all of these CFAE sites are ablated in combination with PVI, procedural outcomes improve particularly in subjects with persistent AF. 12, [15] [16] [17] This result has been confirmed by recently published meta-analyses. 18, 19 For some subjects, CFAE regions encompassing all CFAE types may be extensive, 6 at times occupying >20% of the LA surface area. Although ablating all of these regions may potentially have benefit, such extensive ablation prolongs procedure time, increases the risk of procedural complication, and may reduce long-term atrial function. Ideally, if passive types of CFAE could be distinguished from important CFAE sites, operators could selectively target areas requiring ablation while avoiding the rest of the atrium. Only limited data exist as to which CFAE sites are critical and which are passive. Performing PV antral isolation before CFAE ablation has been shown to reduce the total amount of CFAE, thus performing PV isolation first may eliminate some unimportant CFAE sites. 20 Some have proposed administration of intravenous antiarrhythmics as a way of organizing passively activated areas while highlighting critical regions of CFAE. 21 Others have proposed targeting overlapping CFAE and dominant frequency regions 22 ; however, the role of dominant frequency in AF ablation remains unsettled. 23 In one large retrospective study of hundreds of EGMs, those exhibiting a high percentage of CEA were most likely to be associated with AF termination or increases in AFCL. 7 Further study in human AF has shown that CEA is highly prevalent in antral sites in paroxysmal AF, correlating with an increased efficacy of PVI alone in paroxysmal subjects. 24 Early studies with the CEA algorithm used in this study also showed that CEA sites may represent a unique subset of points not currently identified by standard automated CFAE algorithms. 25 However, in this study, we showed that selective targeting of CEA sites was associated with a worse outcome compared with ablation of all CFAE sites. This would seem to contradict earlier evidence supporting the importance of CEA sites. Limited data exist as to the clinical relevance of CEA sites, but 1 human study did suggest that CEA sites may be more associated with sites of passive atrial activation compared with CFAE sites, demonstrating short CLs. 26 The better outcome in group I (the generalized arm), and the increased incidence of repeat procedures in group II (the selective arm), would certainly support this hypothesis. Interestingly, some studies have suggested that more extensive CFAE ablation could increase the risk of recurrent AT or AFL. However, the fact that more extensive CFAE ablation in group I resulted in better outcome and fewer repeat procedures in this study would argue against this. This may suggest that ablating the appropriate target and completely eliminating it may be more critical to procedural success than the actual volume of ablation. Some have also hypothesized that more extensive LA ablation may improve outcome by debulking the atrial tissue as opposed to targeting any specific signal. Whether this is true or not cannot be established from this study.
Clinical Implications
This study would suggest that a generalized approach to adjuvant CFAE ablation remains the best approach compared with selective targeting of CEA sites. Whether other selective approaches would be of more benefit, such as the targeting of rapid CLs or targeting regions of rotor activity, requires further clinical investigation.
Study Limitations
This study is limited by its small sample size, although even with the limited numbers of patients, significant differences were demonstrated between the 2 groups. The methods of the study also required that CFAE ablation be performed before PVI. As mentioned above, evidence has shown that the size of CFAE regions may be decreased after PVI. 20 Thus, the total amount of CFAE ablation time may have been reduced in group I had PVI been performed first. Presumably, the size of CEA areas may also have been reduced post-PVI as well, so the relative difference in ablation time may have remained constant. The study was designed to perform CFAE ablation first to assess its effect on AFCL and AF termination rates separate from PVI. The study also included a mixed population of high-burden paroxysmal and persistent patients with AF. This was done because of catheter labeling restrictions in the United States at the time of the study. We did demonstrate in the persistent subgroup that the generalized approach was still superior, but the magnitude of difference in the study may have been larger had we restricted it to persistent AF only. CFAE ablation is variable among centers and has been subjective in prior studies. Although a strength of this study was the use of 2 types of CFAE defined objectively by software algorithms, our results may not apply to other definitions of CFAE. We also did not have a control group in whom no CFAE ablation was performed, therefore, we do not know the extent to which added CFAE ablation changed outcomes compared with PVI alone in this population.
Conclusions
CEA ablation+PVI result in a similar incidence of acute AF termination with significantly less RF time. However, incidence of repeat procedures and long-term recurrence of AF/ AFL/AT are significantly lower using generalized CFAE ablation+PVI. 
CLINICAL PERSPECTIVE
Ablation of complex fractionated atrial electrograms (CFAE) for atrial fibrillation (AF) ablation has been reported with mixed results in combination with pulmonary vein isolation. One explanation is that the ideal type of CFAE target has not been adequately defined. In this study, we sought to compare whether a selective CFAE ablation strategy, targeting only sites of continuous electric activity, would produce similar results to more extensive, generalized CFAE ablation when combined with pulmonary vein isolation. Both strategies were objectively guided by automated software algorithms. Although the continuous electric activity strategy resulted in similar acute AF termination rates with significantly less RF time compared with generalized CFAE ablation, the generalized strategy had significantly fewer repeat procedures and less long-term recurrence of AF. Based on these results, it would seem that sites exhibiting continuous electric activity are not important to long-term procedural success of AF ablation and may represent passive sites of CFAE that do not need to be targeted. Further research is required to determine if other specific subsets of CFAE can act as more selective targets during ablation of persistent AF.
